Thyroid Associated Ophthalmopathy Clinical Trials

9 recruitingLast updated: May 13, 2026

There are 9 actively recruiting thyroid associated ophthalmopathy clinical trials across 6 countries. Studies span Phase 3, Not Applicable, Phase 2, Phase 4. Top locations include Shanghai, Shanghai Municipality, China, Bergen, Hordaland, Norway, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


Thyroid Associated Ophthalmopathy Trials at a Glance

9 actively recruiting trials for thyroid associated ophthalmopathy are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Shanghai, Bergen, and Guangzhou. Lead sponsors running thyroid associated ophthalmopathy studies include Haukeland University Hospital, Janjira Petsuksiri, and Althaia Xarxa Assistencial Universitària de Manresa.

Browse thyroid associated ophthalmopathy trials by phase

Treatments under study

About Thyroid Associated Ophthalmopathy Clinical Trials

Looking for clinical trials for Thyroid Associated Ophthalmopathy? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Thyroid Associated Ophthalmopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Thyroid Associated Ophthalmopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease

Thyroid Associated Ophthalmopathy
Haukeland University Hospital60 enrolled1 locationNCT04936854
Recruiting

Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated Ophthalmopathy

Thyroid Associated Ophthalmopathy
Second Affiliated Hospital, School of Medicine, Zhejiang University500 enrolled1 locationNCT07124572
Recruiting

Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy

Thyroid Associated Ophthalmopathy
Shanghai Changzheng Hospital150 enrolled1 locationNCT06590220
Recruiting
Phase 4

A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy

Thyroid Associated Ophthalmopathy
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University60 enrolled1 locationNCT06927375
Recruiting
Phase 2Phase 3

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Thyroid DiseasesEndocrine System DiseasesThyroid Eye Disease+9 more
Sling Therapeutics, Inc.75 enrolled2 locationsNCT06112340
Recruiting
Not Applicable

Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.

Surgical Procedure, UnspecifiedThyroid Associated Ophthalmopathy
Althaia Xarxa Assistencial Universitària de Manresa12 enrolled1 locationNCT04662190
Recruiting
Phase 3

Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)

Thyroid Associated Ophthalmopathy
Janjira Petsuksiri68 enrolled1 locationNCT06392906
Recruiting
Phase 3

Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)

Thyroid Associated OphthalmopathyGraves OphthalmopathyThyroid Associated Orbitopathy
Lund University80 enrolled1 locationNCT03131726
Recruiting
Not Applicable

Multi-model Image of Doxycycline in TAO

Thyroid Associated Ophthalmopathy
Sun Yat-sen University20 enrolled1 locationNCT05112211